INDBInternet News Database 2.5 Updated 1 min ago · 414 sources Show or hide images Light or dark

Osimertinib-Savolitinib Boosts Survival in MET+ NSCLC

1 source1 article First seen Updated United States

Save Compare coverage

Summary

The targeted doublet extended progression-free and overall survival in patients with MET-altered lung cancer that had progressed on osimertinib -- pointing to a potential new treatment option.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Osimertinib-Savolitinib Boosts Survival in MET+ NSCLC

    The targeted doublet extended progression-free and overall survival in patients with MET-altered lung cancer that had progressed on osimertinib -- pointing to a potential new treatment option.